Sign Up to Receive the Latest Trading Tips and News from Prosper

    March 21, 2019

    BIIB Goes Bye-Bye

    Biogen is having a bad day. The investors (the new ones anyway) are feeling the reeling pain of investing into biotech names. This is the truth of reward to risk. When you play in high-beta names as an investor, unfortunately, this can be an outcome. Biogen (Ticker: BIIB) is discontinuing their Alzheimer drug trial. During […]

    Read Article